NYC-based Medivis, whose SurgicalAR tool lets radiologists and surgeons holographically render MRI and CT images, raised a $20M Series A led by Thrive Capital
Startups are designing augmented-reality systems to give doctors 'X-ray vision … FinSMEs : Medivis Raises $20M in Series A Funding Tweets: @startupreport : Radiologist-founded augmented reality startup raises $20M from investors for expansion Radiologist-founded startup gets $20M investment for expansion of augmented reality tech #AR #investment https://news.google.com/...
Context & Ripple Effects
Surgical visualization startups have been quietly accumulating capital for years: Activ Surgical raised a $15M round in 2020 for real-time surgeon intelligence, and Proximie followed with a $38M Series B in 2021 for AR-based virtual collaboration between surgeons. Medivis' $20M Series A extends that line from collaboration software into holographic rendering of MRI and CT scans at the point of care.
The investor is the notable part: Thrive Capital, whose profile runs through large consumer-platform bets like Shopify, is now backing a radiologist-founded clinical imaging tool — a signal that top-tier generalist funds are crossing over into health-tech visualization rather than leaving it to specialist health funds like aMoon or Novo Holdings.
First-order effects
- Medivis gets expansion capital to scale SurgicalAR beyond its current footprint, directly competing for hospital pilots with better-funded AR rival Proximie and AI-visualization player Activ Surgical.
- Thrive Capital gains an early position in clinical augmented reality, diversifying a portfolio otherwise weighted toward consumer internet and commerce platforms.
Second-order effects
- Radiology software vendors such as Gleamer, which just raised a €27M Series B behind its FDA-cleared BoneView, now compete for the same hospital imaging budgets that Medivis' AR rendering targets — pushing vendors toward bundling visualization with diagnostic AI.
- Hospitals evaluating AR surgical tools gain leverage as funded competitors multiply, likely pressuring pricing and accelerating procurement timelines across the category.
Third-order effects
- If funding cadence holds — Activ, Proximie, Gleamer, Rad AI, Qure.ai, and now Medivis within a few years — surgical and radiology imaging consolidates into a platform layer where regulatory clearances and installed imaging-data access become the durable moats, squeezing out point-tool vendors.
The trend: Venture capital is consolidating around AI- and AR-enabled medical imaging platforms, with generalist mega-funds increasingly joining specialist health investors in the category.